Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Clinical trial NCT07516093 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07516093
Sponsor: Nurix Therapeutics, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

B-cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2026-06-01
Primary completion: 2029-10-01
Enrollment: 620

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.